KURA Kura Oncology (KURA) Q2 FY26 earnings call
Kura Oncology reported a strong second quarter, with KOMZIFTI rapidly establishing commercial leadership in new patient starts for relapsed/refractory NPM1-mutant AML, driven by its differentiated profile and effective commercial execution. The company continues to advance ziftomenib's clinical development towards broader AML indications, including frontline and FLT3 combinations, while darlifarnib is emerging as a promising precision oncology platform in solid tumors. Kura maintains a disciplined capital allocation strategy to support these two independent growth franchises.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.